SLC6A2 and gastric cancer: The predominance of the sympathetic nervous system’s activity in patients with gastric cancer, through increased heart rates, elevated plasma free metanephrine and normetanephrine, and increased expression of the norepinephrine transporter in tumor cells, is a negative prognostic factor for these patients.